Home › Castration-Resistant Prostatic Cancer › Tennessee
Castration-Resistant Prostatic Cancer clinical trials in Tennessee
5 studies for Castration-Resistant Prostatic Cancer are looking for participants at sites in Tennessee.
Cities in Tennessee
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- Tennessee Cancer Specialists, Knoxville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07225946A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Tennessee Oncology - Chattanooga, Chattanooga
- Tennessee Oncology Nashville, Nashville
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 25, 2026 · NCT07164443A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
- Tennessee Oncology, Nashville
RecruitingPhase 1
Ages 18 and older · Men · Updated Sep 24, 2026 · NCT07719361A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- The West Clinic, PLLC dba West Cancer Center ( Site 0005), Germantown
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT06863272Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- Sarah Cannon Research, Nashville
RecruitingPhase 1
Ages 18 to 100 · Men · Updated Aug 13, 2026 · NCT05519449From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.